362 related articles for article (PubMed ID: 34125470)
1. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
Lv M; Xue G; Cheng H; Meng P; Lian X; Hölscher C; Li D
Brain Behav; 2021 Aug; 11(8):e2231. PubMed ID: 34125470
[TBL] [Abstract][Full Text] [Related]
2. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Zhang Z; Hao L; Shi M; Yu Z; Shao S; Yuan Y; Zhang Z; Hölscher C
J Parkinsons Dis; 2021; 11(2):529-543. PubMed ID: 33523018
[TBL] [Abstract][Full Text] [Related]
4. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
5. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
6. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
7. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Cao L; Li D; Feng P; Li L; Xue GF; Li G; Hölscher C
Neuroreport; 2016 Apr; 27(6):384-91. PubMed ID: 26918675
[TBL] [Abstract][Full Text] [Related]
8. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce
Zhang L; Li C; Zhang Z; Zhang Z; Jin QQ; Li L; Hölscher C
Parkinsons Dis; 2022; 2022():1428817. PubMed ID: 36419409
[TBL] [Abstract][Full Text] [Related]
9. The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD.
Li C; Liu W; Li X; Zhang Z; Qi H; Liu S; Yan N; Xing Y; Hölscher C; Wang Z
Brain Behav; 2020 Mar; 10(3):e01505. PubMed ID: 31960630
[TBL] [Abstract][Full Text] [Related]
10. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
Cao Y; Hölscher C; Hu MM; Wang T; Zhao F; Bai Y; Zhang J; Wu MN; Qi JS
Eur J Pharmacol; 2018 May; 827():215-226. PubMed ID: 29551659
[TBL] [Abstract][Full Text] [Related]
11. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
13. A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
Zhang Z; Shi M; Li Z; Ling Y; Zhai L; Yuan Y; Ma H; Hao L; Li Z; Zhang Z; Hölscher C
Parkinsons Dis; 2023; 2023():7427136. PubMed ID: 37791037
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Su Y; Liu N; Zhang Z; Li H; Ma J; Yuan Y; Shi M; Liu J; Zhao Z; Zhang Z; Holscher C
Eur J Pharmacol; 2022 Jul; 926():175029. PubMed ID: 35584709
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
[TBL] [Abstract][Full Text] [Related]
17. [Resveratrol protects dopaminergic neurons in a mouse model of Parkinson's disease by regulating the gut-brain axis
Gui J; Sun X; Wen S; Liu X; Qin B; Sang M
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):270-279. PubMed ID: 38501412
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
Zhang L; Zhang L; Li L; Hölscher C
J Parkinsons Dis; 2019; 9(1):157-171. PubMed ID: 30741689
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Zhang Y; Chen Y; Li L; Hölscher C
Behav Brain Res; 2015 Oct; 293():107-13. PubMed ID: 26187689
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota.
Zhou X; Lu J; Wei K; Wei J; Tian P; Yue M; Wang Y; Hong D; Li F; Wang B; Chen T; Fang X
Oxid Med Cell Longev; 2021; 2021():9424582. PubMed ID: 34938384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
